Saturday 17 October 2026
Export AURA’s income statement to Excel — free account
Aura Biosciences, Inc.
AURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 2.13% and free cash flow fell 56.3%, each against the same quarter a year earlier.
6.10
0.24
−3.79%
Follow AURA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(64.26%) | (73.52%) | (95.57%) | (53.49%) | |
| (53.86%) | (60.35%) | (76.70%) | (47.42%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(69.17%) | (79.26%) | (107.79%) | (42.04%) | |
Free Cash Flow per Share |
(1.35) | (1.41) | (1.36) | (1.09) | |
Free Cash Flow |
(88.79) | (85.19) | (91.64) | (103.35) | |
Capital Expenditures |
(0.57) | (0.45) | (0.36) | (0.34) | |
| Other line items | |||||
Cash ROIC |
(27.88%) | (30.30%) | (41.28%) | (16.17%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.83 | 0.80 | 0.81 | 0.79 | |
Depreciation/Fixed assets |
0.44 | 0.43 | 0.45 | 0.49 | |
Capex/Depreciation |
(0.50) | (0.40) | (0.33) | (0.32) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.34) | (1.40) | (1.35) | (1.09) | |
Capex per Share |
(0.01) | (0.01) | (0.01) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates